Saturday, October 3, 2026
ExploreSearch
Via News
Markets

Aspen Group Stock Is 2.77% Down So Far On Friday

ViaNews Editorial Team

December 4, 2020

Aspen Group Stock Is 2.77% Down So Far On Friday
Shares of Aspen Group dropped 2.77% to $11.41 at 14:09 EST on Friday, following yesterday's upward trend. The Nasdaq Stock Market is jumping 0.56% to $12,446.80, following yesterday's upward trend, on what at the moment seems, a somewhat positive trend trading session today. Aspen Group's last close was $11.74, 15.34% under its 52-week high of $13.16.

Aspen Group's Sales

The company's growth estimates for the current quarter is a negative 33.3% and positive 75% for the next.

Aspen Group's Revenue

Year-on-year quarterly revenue growth grew by 46.4%, now sitting on 53.87M for the twelve trailing months.

Aspen Group's Stock Top and Bottom Yearly Value

Aspen Group's stock is valued at $11.41 at 14:09 EST, way under its 52-week high of $13.16 and way higher than its 52-week low of $4.65.

Aspen Group's Moving Average

Aspen Group's worth is above its 50-day moving average of $10.96 and above its 200-day moving average of $10.45.

Categories

Markets

Tags

Stock MarketStockWall StreetStock PriceStock Market NowNASDAQMarket SessionIXICThe Nasdaq Stock MarketAspen GroupASPUStock Price Down
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com